Trials / Terminated
TerminatedNCT00322673
Study of XL999 in Patients With Acute Myeloid Leukemia (AML)
A Phase 2 Study of XL999 Administered Intravenously to Subjects With Acute Myeloid Leukemia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Symphony Evolution, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of XL999 when given weekly to patients with relapsed or newly-diagnosed AML. XL999 is a small molecule inhibitor against Flk1/kinase insert domain receptor (KDR), PDGFR, c-Kit, FLT3 and SRC. c-Kit and FLT3 are receptors commonly expressed on AML blasts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL999 | XL999 was administered at a dose of 2.4 mg/kg given as a 4-hour IV infusion weekly for 4 weeks. In the absence of progressive disease and unacceptable toxicity, subjects were to receive XL999 treatment weekly for up to 1 year on this study |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2006-11-01
- Completion
- 2007-05-01
- First posted
- 2006-05-08
- Last updated
- 2010-02-22
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00322673. Inclusion in this directory is not an endorsement.